TrialJournal for immunotherapy of cancer2024

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).

Ju Won Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.